AGENDA MAY 3RD, 2024 SOVEREIGN BALLROOM
7:15 - 7:45 7:45 - 8:10
Breakfast and Registration
Welcome and Announcements Dr. Alon Altman
Pembrolizumab or placebo with chemoradiotherapy Followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/ GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial Gabriel Levin 8:10 - 8:25 Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial l Katie McRae 8:25 - 8:40 Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer Cristina Mitric 8:40 - 8:55
9:00 - 9:45
Mirvetuximab and Antibody-Drug Conjugatest Dr. Katie Moore
9:45 - 10:15 10:15 - 10:45
Coffee and Exhibits
Evaluation of cost-effectiveness analysis of medications in Gynecologic Oncology Dr. Vanessa Carlson Understanding the Drug Funding Process and Health Technology Assessment Dr. Stephanie Snow
10:45 - 11:15
11:15 - 11:45
Drug Approval Process in Canada Dr. Marc Geirnaert
11:45 - 13:00 13:00 - 13:30
Lunch and Exhibits
Exploring Cultural Safety: Enhancing Indigenous Patient Care in Oncology Dr. Brent Jim
Made with FlippingBook - PDF hosting